Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

    November 2023 in “ Clinical Pharmacokinetics
    Jessica Wojciechowski, Vivek S. Purohit, Yeamin Huh, Christopher Banfield, Timothy Nicholas
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results